methyl (2R)-1-[(E)-3-[5-[(Z)-(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl]prop-2-enoyl]pyrrolidine-2-carboxylate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl (2R)-1-[(E)-3-[5-[(Z)-(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl]prop-2-enoyl]pyrrolidine-2-carboxylate
• 化学式: C₂₁H₁₈N₂O₆S
• 分子量: 426.4
• InChiKey: IRJYOPFDJUCVAX-HDEQPKAHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  131
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• P13 kinase gamma inhibitors for the treatment of anaemia
  申请人：Wetzker Reinhard

  公开号：US20090042773A1

  公开（公告）日：2009-02-12

  This present invention is related to the use of selective PD Kinase gamma inhibitors for the manufacture of a medicament for the treatment of disorders related to erythrocyte deficiency. Specifically, the present invention is related to the use of selective PI3 Kinase gamma inhibitors, e.g. substituted azolidinone-vinyl fused-benzene derivatives for the treatment of an anaemia, including haemolytic anaemia, aplastic anaemia and pure red cell anaemia. (I) wherein A, X, Y 1 , Y 2 , Z, n, R 1 and R 2 are described in details in the description hereinafter.